Phase 2 Alzheimer's Disease Trial, Recruiting NCT06191198 Sponsor: University of Chicago Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT06191198
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the person with Primary Progressive Aphasia (PPA):

  • A neurologist and supporting medical assessments have confirmed a diagnosis of PPA
  • English is the main language used for everyday communication
  • Hearing is sufficient (with or without hearing aids) to hold a conversation in a crowded room
  • Vision is sufficient (with or without glasses) to read a newspaper or similar everyday materials
  • A basic technology check can be passed, showing enough ability to use video calling and a web-based program called Communication Bridge™ (training may be provided)
  • A depression screening score falls within an acceptable range (a score of 9 or below on a standard scale)
  • The PPA is at a mild to moderate stage, as assessed by a speech-language pathologist through interview and standardised testing

For the communication partner (a person who joins alongside the PPA participant):

  • The communication partner is 18 years of age or older
  • English is the main language used for everyday communication
  • Hearing is sufficient (with or without hearing aids) to hold a conversation in a crowded room
  • A basic technology check can be passed, showing enough ability to use video calling and the Communication Bridge™ web program (training may be provided)

Who may not be able to join:

  • People who have a dementia diagnosis other than Primary Progressive Aphasia
  • People who are already enrolled in a separate speech-language therapy program during the study period
  • Communication partners who have an existing communication difficulty of their own — such as aphasia or dementia — that would affect their ability to take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Emily Roglaski, PhD, Professor of Neurology

Phone: 773-702-1220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
23 August 2024
Est. completion
15 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Communication Participation Person Centered Goals; Change in Communication Participation; Montgomery Burden Inventory (MBI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov